Truist Financial 将 Mersana Therapeutics 上调至买入评级，目标价为 9.00 美元。 Truist Financial upgraded Mersana Therapeutics to a buy rating with a $9.00 price target.

Truist Financial 将 Mersana Therapeutics （纳斯达克股票代码：MRSN）的评级从持有评级上调至买入评级，目标价为 9.00 美元。 Truist Financial has upgraded Mersana Therapeutics (NASDAQ:MRSN) from a hold rating to a buy rating, with a $9.00 price target. Robert W. Baird、花旗集团、古根海姆和 BTIG Research 也将该股评级上调至买入评级，目标价分别为 5.00 美元、5.00 美元、7.00 美元和 6.00 美元。 Robert W. Baird, Citigroup, Guggenheim, and BTIG Research have also upgraded the stock to a buy rating, setting target prices of $5.00, $5.00, $7.00, and $6.00, respectively. MRSN 的一致评级为“适度买入”，平均目标价为 6.29 美元。 The consensus rating for MRSN is Moderate Buy, with an average target price of $6.29.